Innate Pharma (IPHA) Receivables - Other (2017 - 2025)

Innate Pharma (IPHA) has reported Receivables - Other for 9 consecutive years, with $133140.6 the latest figure, recorded in Q4 2025.

• Quarterly Receivables - Other rose 31.46% year-over-year to $133140.6 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $133140.6 (up 31.46% YoY) and the FY2025 annual result came in at $642944.2, up 534.83% from the prior year.
• Receivables - Other retreated to $133140.6 in Q4 2025 per IPHA's latest filing, from $413077.4 in the prior quarter.
• Over the last five years, Receivables - Other for IPHA reached as high as $6.5 million in Q2 2022 and fell as low as $69415.2 in Q4 2022.
• A 5-year average of $1.2 million and a median of $430715.7 in 2024 frame the typical range for Receivables - Other.
• The largest YoY upside for Receivables - Other was 213.9% in 2022 against a maximum downside of 92.51% in 2022.
• Year by year, Receivables - Other stood at $926294.8 in 2021, then plunged by 92.51% to $69415.2 in 2022, then surged by 70.49% to $118347.2 in 2023, then dropped by 14.42% to $101277.9 in 2024, then soared by 31.46% to $133140.6 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $133140.6, $413077.4, and $101277.9 for Q4 2025, Q2 2025, and Q4 2024 respectively.